Kymera · pitchdeck
Kymera | Investor Presentation Deck | 60 slides
60 pages · 0 arc beats · 0 loops
Kymera | Investor Presentation Deck | 60 slides
Kymera · 2023-06 arc beats above · slides in the middle · loops below · scroll → 0 LOOPS
124681012141618202224262830323436384042444648505254565860
Deck intelligence map
1 coverage by narrative range · generated from this deck JSON
Narrative range 60 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Whole deck 60 slides 100% 60/60 slides 100% 60/60 slides · 277 hits — 0/60 slides
31.7% 19/60 slides · 20 hits 16.7% 10/60 slides — 0/60 slides
— 0/60 slides
Slide inventory
60 every slide · same image gating as the playbook
03
The slide uses a split-layout with a company profile on the left and a list of key accomplishments on the right.summarize
04
TPD = Targeted Protein Degradation. UD = Undrugged. ID = Inadequately Drugged. PK = Pharmacokinetics. PD = Pharmacodynamics. SMI = Small Molecule Inhibitor.present_solution
05
TPD = Targeted Protein Degradation; PK = Pharmacokinetics; PD = Pharmacodynamics; HS = Hidradenitis Suppurativa; AD = Atopic Dermatitis.show_traction
06
The slide uses a dot-matrix representation to indicate therapeutic focus areas for specific drug candidates.present_solution
07
The slide uses a Gantt-style chart to show the progression of various drug programs (IRAK4, IRAKIMiD, STAT3, MDM2, etc.) through discovery, IND enabling, and clplan_implementation
10
The slide uses a biological pathway diagram to illustrate the mechanism of action and a callout box for the therapeutic thesis.present_solution
11
The slide uses a combination of a biological mechanism diagram, a market data table, and a comparative analysis of current therapy limitations.size_opportunity
12
The slide uses a split-screen comparison between healthy volunteer data and patient data.show_traction
13
The slide uses a bulleted list structure to categorize findings between healthy volunteers and patients, concluding with a strategic partnership milestone.show_traction
15
The slide provides a breakdown of patient outcomes including completion and withdrawal reasons.analyze_data
16
HS = Hidradenitis Suppurativa; AD = Atopic Dermatitis; HV = Healthy Volunteers; MAD = Multiple Ascending Dose; LLOQ = Lower Limit of Quantitation.show_traction
17
The chart shows a clear reduction in IRAK4 protein levels in both AD and HS patient groups after 28 days of treatment, bringing them down to or below the baselianalyze_data
18
The slide compares cytokine inhibition efficacy in Healthy Subjects (MAD3), AD patients, and HS patients using two different stimulation methods (LPS and R848).show_traction
19
The chart specifically visualizes IL-6 reduction over time, while the table summarizes max reduction across four markers.show_traction
20
The slide uses individual patient data points (AD-1 to AD-7, HS-1 to HS-12) to show consistent downregulation across cohorts.analyze_data
21
Data presented as mean percentage change with standard error bars; N=7.show_traction
22
The chart tracks patient outcomes over time, showing a shift from severe/moderate to mild categories.show_traction
23
Includes clinical photography, efficacy endpoint table, and biomarker data (cytokines and RNAseq).illustrate_case
24
The slide uses a comparison table to highlight efficacy metrics (EASI, Pruritus NRS) across different time points and benchmarks.show_traction
25
Data compares 'All HS Patients' vs 'Moderate to Severe' subgroups. Includes error bars representing standard error of the mean or 80% confidence intervals.show_traction
26
Data presented across three line charts comparing 'All HS Patients' vs 'Moderate to Severe' subgroups.show_traction
27
The charts demonstrate a shift from higher severity scores (orange/red) to lower severity scores (blue/black) over time.show_traction
28
Includes clinical efficacy table and RNAseq biomarker reduction chart.illustrate_case
29
Includes patient profile, clinical efficacy table, before/after photos, and cytokine biomarker tracking.illustrate_case
30
The table compares KT-474 (Part C) at Day 28 and 42 against external benchmarks at Week 4. Includes extensive footnote citations.compare_peers
31
The footer explicitly notes the absence of Serious Adverse Events (SAEs), infections, or events leading to discontinuation.analyze_data
32
Data presented as mean change from baseline with 90% CI. Includes table of mean values for delta QTc and absolute QTc.analyze_data
33
The slide uses color-coded text (orange) to emphasize key positive outcomes within the bullet points.summarize
35
The diagram illustrates the signaling pathways (TLR, IL-1R, B Cell Receptor) and the specific points of intervention (red asterisks) for the therapy.frame_problem
36
The slide presents two charts: a tumor growth inhibition curve and a PK/PD correlation chart showing drug concentration vs. target degradation over time.show_traction
37
The slide outlines a clinical trial design using a dose-escalation process leading to MTD/RP2D expansion cohorts.plan_implementation
39
Includes a disclaimer/footnote regarding patient population and MYD88 mutation status.show_traction
40
The slide uses a split-layout: left side focuses on clinical data (PK/PD/Safety), right side focuses on strategic positioning and clinical development plan.summarize
42
Includes a table of prevalence/incidence for specific oncology indications and a biological pathway diagram.size_opportunity
43
The slide presents two distinct charts: a tumor volume growth curve and a PK/PD concentration-time profile.show_traction
44
The slide outlines a standard oncology clinical trial design (3+3 or similar dose escalation) followed by cohort expansion.plan_implementation
45
Clinical trial safety data table showing patient counts and percentages for specific adverse events.analyze_data
46
Includes a line chart for PK profiles and a table for PK parameters (Cmax, AUClast, Vd, CL, t1/2).analyze_data
47
The slide presents clinical trial results for KT-333, comparing degradation percentages across three dose levels (DL1, DL2, DL3) over two cycles.show_traction
48
Includes bar charts for SAA/CRP reduction, a longitudinal line chart for biomarker changes, and a scatter plot showing correlation between STAT3 and SOCS3 changshow_traction
49
DL1-3 refers to dose levels 1-3. PK = Pharmacokinetics, PD = Pharmacodynamics, DLT = Dose-Limiting Toxicity, SAE = Serious Adverse Event.show_traction
51
Includes a DepMap CRISPR sensitivity plot and a biological pathway diagram illustrating the feedback loop.present_solution
52
Includes a biological pathway diagram and Western blot data comparing a degrader (KT-253) to an inhibitor (DS-3032).present_solution
53
Includes a table comparing clinical stage and potency metrics (IC50, DC50) across multiple competitors.compare_peers
54
Data presented as tumor volume growth curves and Kaplan-Meier survival plots.show_traction
55
The slide presents five bar charts showing protein levels across different dosing regimens and time points.present_solution
56
Shows two distinct experiments: DFAM-6855 (Whole Blood) and MOLM-13 (Tumor Volume).show_traction
57
The slide title mentions KT-333, but the content refers to KT-253 throughout; this is likely a typo in the source deck.plan_implementation
58
The slide uses a split-layout to contrast mechanism benefits (left) with strategic market opportunity (right).present_solution
60
The image shows the Kymera Therapeutics team at their Nasdaq listing event.state_next_steps